X-Zell Inc. articles

X-ZELL is collaborating with Singapore General Hospital (SGH) and the National University Hospital Singapore (NUH) to explore how X-ZELL single-cell diagnostics may aid in the early detection of clinically significant prostate cancer in whole blood.

The prospectively blinded, 400-patient multi-centre study officially commenced in 2020 and will lay the foundation for the launch of a commercially available blood test as early as 2023.

• Project spearheaded by Singapore&rsqu

X-ZELL is collaborating with one of Germany’s leading cytopathology centres to introduce Cryoimmunostaining™ into routine cytology as a tool to efficiently analyse lung fluids such as bronchoalveolar lavage and pleural effusion and enable near-instant diagnoses through digital on-screen analysis.

According to the German Association of Pathology (BdP), X-ZELL Cryoimmunostaining™ is eligible for reimbursement under the EBM and GOÄ systems.

• 93 per ce